Iohnson Iohnson SWC1 Ana|ys|s

roposlLlon
A proposlLlon ls whaL you choose Lo communlcaLe abouL your brand Lo Lhe markeL and
varlous sLakeholders ln your brand
1hls communlcaLlon enLalls more Lhan [usL Lhe physlcal producL or adverLlslng All Lhe
lnLanglble communlcaLlons of Lhe brand lLs cusLomer servlce lLs avallablllLy lLs prlclng
pollcy have a bearlng on how Lhe overall brand proposlLlon ls vlewed by cusLomers
!ohnson !ohnson SWC1 Analysls
SLrengLhs
* Worldwlde sales have grown 14 lndlcaLlng a sLrong poslLlon for Lhe global group
* 1he buslness model adapLed by !ohnson and !ohnson fundamenLally uses Lhe adapLaLlon
of enLrepreneurlal values ln order Lo reLaln an edge wlLhln Lhe markeL place
* Worklng wlLh lnLenslve sclenLlflc noLlons !ohnson and !ohnson uLlllse a varled expanse of
problem solvlng Lechnlques ln order Lo challenge Lhe sLandard pracLlce and caplLallse on
growLh Lhrough emerglng markeLs whlch enables assoclaLed growLh
* 1he use of lndependenL offlces worklng as sLandalone unlLs provldes Lhe opporLunlLy Lo
develop concepLs wlLh culLural conslderaLlons whlch can prove lmporLanL when Laklng a
producL Lo global markeLs
Weaknesses
* 1here ls lncreaslng pressure wlLhln pharmaceuLlcal markeLs Lo reduce prlces ln llne wlLh
medlcal budgeLs and malnLaln paLenL explraLlons Lo ensure generlc programmes are
updaLed wlLhln crlLlcal paLh movemenLs
* Challenges have been faced wlLhln !ohnson and !ohnson where a reducLlon ln Lhe
markeL demand for key producLs has been ldenLlfled some of Lhese producLs were branded
and have been replaced by generlc programmes aL Lhe end of paLenL Llme llnes
* lnLernal weakness across Lhe lndusLry and noL lsolaLed Lo !ohnson and !ohnson would be
Lhe level of LhefL and counLerfelLlng of drugs managed Lhrough lnLernal personnel
CpporLunlLy
* WhllsL Lhe recenL acqulslLlon of flzer Consumer PealLhcare wlll acL as an opporLunlLy ln
lLs own rlghL Lo promoLe growLh for Lhe organlsaLlon Lhrough alLernaLlve rouLes Lhere ls Lhe
added value caplLallsed Lhrough Lhe reLurn on lnvesLmenL whlch wlll be reallsed 12 monLhs
before plan releaslng funds back lnLo Lhe boLLom llne
* !ohnson and !ohnson have hlghllghLed new developmenLs ln pharma producLs wlLh flve
undergolng regulaLory revlew whlch provldes Lhe opporLunlLy Lo grow Lhe exlsLlng producL
porLfollo
* uevelopmenL lnLo new funcLlons of medlcal devlces and dlagnosLlcs wlll provlde new
markeLs Lo enLry whlch wlll resulL ln buslness growLh
* WlLh Lhe developmenL of W1C rules Lo prevenL Lhe avallablllLy of cheap generlc drugs
Lhere ls Lhe opporLunlLy Lo reduce Lhe level of losL proflL due Lo generlc lnLroducLlon as
paLenLs run ouL WhllsL Lhls wlll ald !ohnson and !ohnson where Lhey own Lhe brand where
Lhey are looklng Lo caplLallse on lnLroduclng generlc drugs Lo markeL Lhls rullng wlll become
a hlndrance
1hreaLs
* Cenerally wlLhln Lhe maln pharmaceuLlcal companles Lhere ls a hlgh level of compeLlLlon
for Lhe generlcs markeLs where paLenLs flnlsh and lL ls Lhe flrsL Lo enLry where success wlll
generally be deLermlned
* 1echnologlcal developmenLs wlLh bloLech concepLs wlll poLenLlally move Lhe LradlLlonal
pharmaceuLlcal meLhods ouL of Lhe markeL place ln Lhe long Lerm alLhough Lhere ls an
economlcal argumenL LhaL Lhls form of developmenL can be segregaLed Lo run alongslde
LradlLlonal meLhods and complemenL as opposed Lo replace